SCHEMBL2116833

SCHEMBL2116833

Cc1cc(NS(=O)(=O)c2ccco2)cc(-c2ccc(C#N)cc2)c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SYK P43405 1/20 0.48
HSD11B1 P28845 3/20 0.45
SGK1 O00141 1/20 0.43
MYC P01106 3/20 0.43
IDO1 P14902 1/20 0.43
TP53 P04637 1/20 0.42
THRB P10828 1/20 0.42
BCL2 P10415 1/20 0.41
BECN1 Q14457 1/20 0.41
KCNH2 Q12809 1/20 0.41
SCN10A Q9Y5Y9 1/20 0.41
ALPL P05186 3/20 0.41
DRD2 P14416 1/20 0.39
HTR2A P28223 1/20 0.39
HTR2C P28335 1/20 0.39
DRD3 P35462 1/20 0.39
HTR6 P50406 1/20 0.39
KAT6A Q92794 1/20 0.39
CCR2 P41597 1/20 0.39
ACLY P53396 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2120200 0.81 ACLY (0.48) HSD11B1SGK1MYCKAT6ACCR2
SCHEMBL2118331 0.79 HSD11B1 (0.62) HSD11B1IDO1TP53THRBDRD2
SCHEMBL2117206 0.77 SYK (0.46) SYKSGK1TP53THRBKAT6A
SCHEMBL2117286 0.76 SYK (0.48) SYKSGK1TP53KAT6ACCR2
SCHEMBL2117837 0.74 STAT3 (0.60) HSD11B1IDO1ALPLDRD2HTR2A
SCHEMBL2119847 0.70 CCR2 (0.41) HSD11B1SGK1MYCTP53THRB
SCHEMBL2118454 0.70 HSD11B1 (0.51) HSD11B1TP53THRBALPLDRD2
SCHEMBL23873781 0.69 CYP2A6 (0.58) HSD11B1KCNH2SCN10A
SCHEMBL29059425 0.67 CCR2 (0.49) SYKSGK1CCR2ACLY
SCHEMBL2120543 0.66 KAT6A (0.53) TP53KAT6A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120095012-A1 TOLUIDINE SULFONAMIDES AND THEIR USE ELARA PHARMACEUTICALS GMBH (DE) 2012-04-19 US disclosed
EP-2382190-A1 TOLUIDINE SULFONAMIDES AND THEIR USE AS-INHIBITORS European Molecular Biology Laboratory (EMBL) (DE) 2011-11-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120095012-A1 TOLUIDINE SULFONAMIDES AND THEIR USE HIF1A, HIF1AN, EGLN3 SYK 393/4885HSD11B1 3376/4885SGK1 4188/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.